Feb 25 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop next-generation oral drugs for ...
The intestinal wall is like a gatekeeper, absorbing certain compounds while keeping others from passing through. To the medical field, the gastrointestinal tract is more like a black box, said Thomas ...
Drug delivery utilizes various methods and/or carriers to transport therapeutic agents to the tissue, organ, cell, or subcellular organ of interest for release and absorption. Some of the primary ...
Fresh off the launch of its semaglutide pill, Novo Nordisk has entered a partnership with a start-up that aims to increase the bioavailability of oral peptides. Vivtex Corporation, launched in 2018 as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results